체외 대장암 스크리닝 검사 시장 규모는 2023년 237억 9,000만 달러로 예측 기간(2025-2032년) 동안 11.1%의 CAGR로 2024년 264억 3,000만 달러에서 2032년 718억 8,000만 달러로 성장할 것으로 예상됩니다.
체외 대장암 스크리닝 검사 시장은 대장암 및 직장암의 증가와 혁신적인 유전자 검사법의 도입으로 인해 크게 성장할 것으로 예상됩니다. 이러한 검사에는 구아이악 FOB 대변 검사, 메틸화 유전자 분석, 대변 잠혈 검사 등 대장암의 조기 발견을 용이하게 하는 다양한 스크리닝 옵션들이 포함됩니다. 이러한 검사는 영상 시스템을 이용한 첨단 체외 기술로 이루어지기 때문에 진료소, 병원, 진단 연구소에서 시행하기에 적합합니다. 또한, 암 검진을 의무화하는 정부 규제와 DNA 및 유전자 바이오마커를 활용한 첨단 검사에 대한 소비자 수요 증가는 향후 몇 년 동안 이 시장 부문의 성장을 더욱 촉진할 것으로 예상됩니다.
In-Vitro Colorectal Cancer Screening Tests Market size was valued at USD 23.79 Billion in 2023 and is poised to grow from USD 26.43 Billion in 2024 to USD 71.88 Billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).
The market for in-vitro colorectal cancer screening tests is poised for significant growth, driven by increasing incidences of colon and rectal cancers and the introduction of innovative genetic testing methods. These tests encompass a variety of screening options such as guaiac FOB stool tests, methylated gene assays, and faecal occult blood tests, which are minimally invasive and facilitate the early detection of colorectal cancer. They operate through advanced in-vitro techniques that utilize imaging systems, making them suitable for implementation in clinics, hospitals, and diagnostics laboratories. Moreover, supportive government regulations mandating cancer screenings, alongside heightened consumer demand for advanced tests leveraging DNA and genetic biomarkers, further bolster this market segment's expansion in the coming years.
Top-down and bottom-up approaches were used to estimate and validate the size of the In-Vitro Colorectal Cancer Screening Tests market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
In-Vitro Colorectal Cancer Screening Tests Market Segmental Analysis
Global In-Vitro Colorectal Cancer Screening Tests Market is segmented by test type, end user and region. Based on test type, the market is segmented into fecal occult blood tests, biomarker tests and CRC DNA screening tests. Based on end user, the market is segmented into hospitals, clinics, diagnostics laboratories and ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the In-Vitro Colorectal Cancer Screening Tests Market
The In-Vitro Colorectal Cancer Screening Tests market is experiencing notable growth driven by several key factors. The increasing incidence of colorectal cancer, influenced by an ageing population, unhealthy lifestyle choices, and rising diabetes rates, is propelling demand. Furthermore, heightened awareness of these screening tests, coupled with the widespread use of biomarkers, is contributing to market expansion. The desire for less invasive diagnostic methods and recent innovations in the field are expected to boost demand further. Additionally, awareness of the rising prevalence of colorectal cancer in younger populations and regulatory requirements for screening are also supporting market growth, allowing consumers to choose from various screening options tailored to individual needs.
Restraints in the In-Vitro Colorectal Cancer Screening Tests Market
The in-vitro colorectal cancer screening tests market may face several hindrances that could impede its growth. Key challenges include a shortage of skilled personnel and established screening protocols in developing countries, which limit effective implementation. Additionally, the insufficient reimbursement frameworks for in-vitro colorectal cancer testing further constrain market expansion. The Asia-Pacific region, in particular, is grappling with a significant deficit of qualified medical professionals, exacerbated by an aging population and increased physician workloads. Furthermore, the absence of supportive policies and initiatives aimed at raising awareness and encouraging the utilization of these tests may also hinder market development.
Market Trends of the In-Vitro Colorectal Cancer Screening Tests Market
The In-Vitro Colorectal Cancer Screening Tests market is witnessing significant growth driven by an alarming increase in colorectal cancer incidence among populations worldwide. Heightened public awareness surrounding the benefits of early detection and timely intervention further fuels this expansion. Technological advancements, particularly the integration of genetic testing into screening processes, are revolutionizing the market, facilitating not only early diagnosis but also the development of tailored treatment protocols. These innovations enhance the ability to curb the proliferation of cancerous cells, thereby reducing associated health risks. Collectively, these dynamics position the In-Vitro colorectal cancer screening segment for robust growth in the foreseeable future.